23 September 2024
UBS Principal Capital Asia Ltd. has divested its holdings in Concord Biotech Ltd., Five-Star Bus Fin Ltd., IIFL Securities Ltd., and Marksans Pharma Ltd. for a total of Rs 480 crore, as per bulk deal data on the NSE. The details of the sales are as follows:
- Concord Biotech Ltd.: UBS sold 7.4 lakh shares, representing a 0.7% stake at Rs 2589.86 each, totaling Rs 191 crore.
- Five-Star Bus Fin Ltd.: UBS offloaded 15.8 lakh shares, representing a 0.54% stake at Rs 804.74 each, totaling Rs 127 crore.
- IIFL Securities Ltd.: UBS put up 17.1 lakh shares for sale, representing a 0.55% stake at Rs 309.84 each, totaling Rs 53 crore.
- Marksans Pharma Ltd.: UBS offered 34.01 lakh shares for sale, representing a 0.75% stake at Rs 317.22 each, totaling Rs 107 crore.
.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Pre Ipo
Upcoming IPO
Unicorn
Mutual Fund License No.:
IRDA Code (1):
IRDA Code (2):
Startup India Certificate No.:
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India